The chart below shows how HSIC performed 10 days before and after its earnings report, based on data from the past quarters. Typically, HSIC sees a +3.96% change in stock price 10 days leading up to the earnings, and a +3.06% change 10 days following the report. On the earnings day itself, the stock moves by -2.05%. This data can give you a slight idea of what to expect for the next quarter's release.
Positive
Strategic Plan Success: Our business performed well during the third quarter, driven by the successful implementation of our BOLD+1 Strategic Plan that is resulting in growth and efficiency throughout Henry Schein and a strong contribution from high growth, high margin products and services.
Market Share Gains: We believe we continue to steadily gain market share in our dental and medical distribution businesses following last year's cyber incident.
Global Dental Equipment Stability: Our dental equipment business is showing ongoing stability in North America and increased investment by customers across Europe, Australia, and New Zealand.
Operating Income Target Exceeded: We are reporting another quarter exceeding our target of 40% of operating income generated by our high-growth, high-margin businesses and we expect to exceed the target this particular target of the 40% target for fiscal 2024.
Financial Performance Exceeded Expectations: We exceeded our financial expectations for the quarter.
Negative
Net Income Decline: GAAAP net income decreased to $99 million or $0.78 per diluted share, compared to prior year GAAAP net income of $137 million or $1.05 per diluted share.
Operating Margin Decline: GAAAP operating margin for the third quarter of 2024 was 4.94%, a 140 basis point decline compared to the prior year GAAAP operating margin.
Net Income Decline: Non-GAAAP net income was $155 million or $1.22 per diluted share, down from prior year non-GAAAP net income of $173 million or $1.32 per diluted share.
Sales Decline Analysis: Total sales decreased by 1.6% compared to the third quarter of 2023, reflecting a 2.6% decrease in LCI sales for the quarter.
Adjusted EBITDA Comparison: Adjusted EBITDA for the third quarter of 2024 was $268 million compared to $278 million in the third quarter of 2023.
Henry Schein, Inc. (HSIC) Q3 2024 Earnings Call Transcript
HSIC.O
-0.59%